Acurx Pharmaceuticals, Inc , a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections.
infoAcurx Pharmaceuticals is a micro cap stock with a total market cap of 26.92M.
infoThey trade on the NASDAQ and had their IPO 2 years and 1 month ago.
infoAcurx Pharmaceuticals currently employs 4 people.
infoAs of Wednesday, Aug 23 2023, Acurx Pharmaceuticals’s share price is $2.07.
News Relating to Acurx Pharmaceuticals
PRNewsWire
Acurx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 11-13, 2023
Tuesday Aug 22 2023 at 07:01
STATEN ISLAND, N.Y. , Aug. 22, 2023 /PRNewswire/ — Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that David P.
PRNewsWire
Acurx Pharmaceuticals to Present at the Emerging Growth Conference on July 12, 2023
Tuesday Jun 20 2023 at 07:01
Acurx invites individual and institutional investors, financial advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth Conference. STATEN ISLAND, N.Y.
Seeking Alpha
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2022 Earnings Call Transcript
Thursday Mar 16 2023 at 14:20
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q4 2022 Earnings Conference Call March 16, 2023 8:00 AM ET Company Participants Robert Shawah – Co-Founder & Chief Financial Officer David Luci – President & Chief Executive Officer Conference Call Participants Jason McCarthy – Maxim James Molloy – Alliance Global Partners Operator Greetings and welcome to the Acurx Pharmaceutical Fourth Quarter and Full Year 2022 Financial Results and Business Update. [Operator Instructions] As a reminder, this conference is being recorded.
PRNewsWire
Acurx Pharmaceuticals to Present at the Emerging Growth Conference on January 25, 2023
Monday Jan 16 2023 at 08:01
Acurx invites individual and institutional investors, financial advisors and analysts to attend its real-time, interactive question and answer session at the Emerging Growth Conference STATEN ISLAND, N.Y. , Jan. 16, 2023 /PRNewswire/ — Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, is pleased to announce that it has been invited to present at the Emerging Growth Conference on January 25, 2023.
Seeking Alpha
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2022 Earnings Call Transcript
Monday Nov 14 2022 at 11:14
Start Time: 08:30 January 1, 0000 8:49 AM ET Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q3 2022 Earnings Conference Call November 14, 2022, 08:30 AM ET Company Participants David Luci – President and CEO Robert Shawah – Co-Founder and CFO Conference Call Participants Jason McCarthy – Maxim Group Operator Greetings. Welcome to Acurx Pharmaceuticals, Inc. to Discuss 2022 Third Quarter Financial Results on November 14, 2022.
PRNewsWire
Acurx Pharmaceuticals, Inc. to Discuss 2022 Third Quarter Financial Results on November 14, 2022 Conference Call and Provide Business Update
Tuesday Nov 01 2022 at 08:01
STATEN ISLAND, N.Y. , Nov. 1, 2022 /PRNewswire/ — Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its 2022 third quarter financial results on Monday, November 14, 2022, at 8:30 am ET before the U.S. financial markets open.
Seeking Alpha
Acurx Pharmaceuticals, Inc. (ACXP) CEO David Luci on Q2 2022 Results – Earnings Call Transcript
Tuesday Aug 16 2022 at 11:53
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q2 2022 Earnings Conference Call August 16, 2022 8:30 AM ET Company Participants Robert Shawah – CFO David Luci – CEO Conference Call Participants Jim Molloy – Alliance Global Partners Operator Greetings. Welcome to Acurx Pharmaceuticals’ Second Quarter 2022 Results and Business Update.
PRNewsWire
Acurx Pharmaceuticals, Inc. to Discuss 2022 Second Quarter Financial Results on August 16, 2022 Conference Call and Provide Business Update
Thursday Aug 04 2022 at 08:01
STATEN ISLAND, N.Y. , Aug. 4, 2022 /PRNewswire/ — Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its 2022 second quarter financial results on Tuesday, August 16, 2022, at 8:30 am ET before the U.S. financial markets open.
Seeking Alpha
Acurx Pharmaceuticals, Inc.’s (ACXP) CEO David Luci on Q1 2022 Results – Earnings Call Transcript
Wednesday May 11 2022 at 15:58
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Rob Shawah – Chief Financial Officer David Luci – President and Chief Executive Officer Conference Call Participants Chad Yahn – Maxim Group Joanne Lee – Maxim Group Operator Greetings and welcome to the Acurx Pharmaceuticals, Inc. First Quarter 2022 Results and Business Update. At this time, all participants are in a listen-only mode.
PRNewsWire
Acurx Pharmaceuticals, Inc. to Discuss 2022 First Quarter Financial Results on May 11, 2022 Conference Call and Provide Business Update
Friday Apr 29 2022 at 08:01
STATEN ISLAND, N.Y. , April 29, 2022 /PRNewswire/ — Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its 2022 first quarter financial results on Wednesday, May 11 2022, at 8:30 am ET before the U.S. financial markets open.
Seeking Alpha
Acurx Pharmaceuticals, Inc. (ACXP) CEO David Luci on Q3 2021 Earnings Call Transcript
Monday Nov 15 2021 at 11:46
Acurx Pharmaceuticals, Inc. (ACXP) CEO David Luci on Q3 2021 Earnings Call Transcript
PRNewsWire
Acurx Pharmaceuticals to Discuss 2021 Third Quarter Financial Results on November 15, 2021 Conference Call and Provide Business Update
Wednesday Oct 27 2021 at 08:01
STATEN ISLAND, N.Y., Oct. 27, 2021 /PRNewswire/ — Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its 2021 third quarter financial results on Monday, November 15, 2021, at 8:30 am ET before the U.S. financial markets open.
PRNewsWire
Acurx Presents Positive Ibezapolstat Microbiome Data from Its Phase 2a Trial at IDWeek
Monday Oct 04 2021 at 09:00
STATEN ISLAND, N.Y., Oct. 4, 2021 /PRNewswire/ — Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that a scientific abstract and poster were presented on September 29 th at the Infectious Disease Society of America (IDSA) IDWeek™ 2021 Virtual Conference entitled: “An Open-label Phase 2a study of Ibezapolstat, a Unique Gram-positive Selective Spectrum (GPSS™) Antibiotic, for Patients with Clostridioides difficile Infection.
Newsfile Corp
CEO Spotlight: Acurx Pharmaceuticals in Focus with CEO David Luci Talking Potentially Transformative Phase 2b Trial, Pipeline, and Potential Near-Term Catalysts
Monday Sep 13 2021 at 08:03
Acurx Pharmaceutical’s CEO tells Soulstring Media why he thinks 2021-22 can be a breakout year for his companyNew York, New York–(Newsfile Corp. – September 13, 2021) – Acurx Pharmaceuticals (NASDAQ: ACXP) is a clinical-stage biopharmaceutical company developing a new class of antibiotics that could present the most meaningful changes to that sector in more than four decades. Its lead program utilizes ibezapolstat to target the debilitating C. difficile infection. Other pipeline programs and drugs are expected to target and treat numerous other gram-positive infections.That strategy could be advantageous on several fronts and…
Seeking Alpha
New Antibiotics Needed For Drug-Resistant Infections, Acurx Pharmaceuticals May Have The Answers
Friday Aug 27 2021 at 01:40
New Antibiotics Needed For Drug-Resistant Infections, Acurx Pharmaceuticals May Have The Answers
PRNewsWire
Acurx Pharmaceuticals to Present at the Emerging Growth Conference on August 18, 2021
Thursday Aug 12 2021 at 08:00
STATEN ISLAND, N.Y. , Aug. 12, 2021 /PRNewswire/ — Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that David P.
PRNewsWire
Acurx Pharmaceuticals to Discuss 2021 Second Quarter Financial Results on August 17, 2021 Conference Call and Provide Business Update
Wednesday Jul 28 2021 at 08:00
STATEN ISLAND, N.Y., July 28, 2021 /PRNewswire/ — Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its 2021 second quarter financial results on Tuesday, August 17, 2021, at 8:30 am ET before the U.S. financial markets open.
PRNewsWire
Acurx Announces New Ibezapolstat Data on Anti-Recurrence Mechanisms in CDI at Prominent International Conference
Thursday Jul 01 2021 at 08:00
STATEN ISLAND, N.Y. , July 1, 2021 /PRNewswire/ — Acurx Pharmaceuticals, Inc. (Nasdaq ACXP) (“Acurx” or the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that using specimens from a Phase 1 healthy volunteer trial and a novel analysis technique, beneficial changes potentially predictive of lower risk of CDI (Clostridioides difficile Infection) recurrence were associated with ibezapolstat compared to vancomycin.
PRNewsWire
ACURX PHARMACEUTICALS, Inc. Announces Closing of INITIAL Public Offering OF common stock AND FULL EXERCISE OF UNDERWRITERS’ OPTION TO PURCHASE ADDITIONAL SHARES
Tuesday Jun 29 2021 at 16:01
STATEN ISLAND, N.Y., June 29, 2021 /PRNewswire/ — Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) (the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today the closing of its previously announced underwritten initial public offering of 2,875,000 newly-issued shares of common stock, including the full exercise by the underwriters of their option to purchase 375,000 additional shares of common stock, at a price to the public of $6.00 per share.
Acurx Pharmaceuticals Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Acurx Pharmaceuticals’s Altman Z-score is -7.25 which is in the distress zone. This indicates a higher risk of financial distress and potential bankruptcy for the company. It can serve as a warning sign of significant financial challenges, requiring careful consideration by potential investors.
Derived from SEC.GOV filing dataopen_in_new
Acurx Pharmaceuticals Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, there has been no insider trading in Acurx Pharmaceuticals.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Cannot compute a percentage difference when there are zeros in the calculation
Cannot compute a percentage difference when there are zeros in the calculation
Cannot compute a percentage difference when there are zeros in the calculation
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Acurx Pharmaceuticals’s Current Ratio of 3.03 is lower than its Industry Group of 4.76 (-36.3% lower)
Acurx Pharmaceuticals’s Current Ratio of 3.03 is lower than its Major Industry Group of 4.32 (-29.9% lower)
Acurx Pharmaceuticals’s Current Ratio of 3.03 is greater than its Sector of 2.6 (16.5% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-0.01 & -1.27)
Cannot compare a negative PE Ratio (-0.01 & -1.1)
Cannot compare a negative PE Ratio (-0.01 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Cannot compute a percentage difference when there are zeros in the calculation
Cannot compute a percentage difference when there are zeros in the calculation
Cannot compute a percentage difference when there are zeros in the calculation
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Acurx Pharmaceuticals’s ROE of -0.55 is lower than its Industry Group of -0.44 (-25.0% lower)
Acurx Pharmaceuticals’s ROE of -0.55 is lower than its Major Industry Group of -0.38 (-44.7% lower)
Acurx Pharmaceuticals’s ROE of -0.55 is lower than its Sector of -0.03 (-1733.3% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Acurx Pharmaceuticals’s ROCE of -0.56 is lower than its Industry Group of -0.42 (-33.3% lower)
Acurx Pharmaceuticals’s ROCE of -0.56 is lower than its Major Industry Group of -0.37 (-51.4% lower)
Acurx Pharmaceuticals’s ROCE of -0.56 is lower than its Sector of -0.04 (-1300.0% lower)
Derived from SEC.GOV filing dataopen_in_new